JP2023513220A - 認知機能低下患者におけるアミロイドβモノマーレベルを減少させる方法 - Google Patents
認知機能低下患者におけるアミロイドβモノマーレベルを減少させる方法 Download PDFInfo
- Publication number
- JP2023513220A JP2023513220A JP2022548088A JP2022548088A JP2023513220A JP 2023513220 A JP2023513220 A JP 2023513220A JP 2022548088 A JP2022548088 A JP 2022548088A JP 2022548088 A JP2022548088 A JP 2022548088A JP 2023513220 A JP2023513220 A JP 2023513220A
- Authority
- JP
- Japan
- Prior art keywords
- subject
- amyloid
- months
- effective amount
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025202377A JP2026041805A (ja) | 2020-02-13 | 2025-11-24 | 認知機能低下患者におけるアミロイドβモノマーレベルを減少させる方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062976325P | 2020-02-13 | 2020-02-13 | |
| US62/976,325 | 2020-02-13 | ||
| PCT/US2021/018023 WO2021163613A1 (en) | 2020-02-13 | 2021-02-12 | Method of decreasing amyloid beta monomer levels in patients with cognitive decline |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025202377A Division JP2026041805A (ja) | 2020-02-13 | 2025-11-24 | 認知機能低下患者におけるアミロイドβモノマーレベルを減少させる方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023513220A true JP2023513220A (ja) | 2023-03-30 |
| JP2023513220A5 JP2023513220A5 (cg-RX-API-DMAC7.html) | 2024-02-19 |
Family
ID=77292728
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548088A Pending JP2023513220A (ja) | 2020-02-13 | 2021-02-12 | 認知機能低下患者におけるアミロイドβモノマーレベルを減少させる方法 |
| JP2025202377A Pending JP2026041805A (ja) | 2020-02-13 | 2025-11-24 | 認知機能低下患者におけるアミロイドβモノマーレベルを減少させる方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025202377A Pending JP2026041805A (ja) | 2020-02-13 | 2025-11-24 | 認知機能低下患者におけるアミロイドβモノマーレベルを減少させる方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230098944A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4103604A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023513220A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220142477A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115397849A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021218735A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL295427A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021163613A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015116923A1 (en) | 2014-01-31 | 2015-08-06 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
| CN116867488A (zh) * | 2020-12-11 | 2023-10-10 | 考格尼申治疗股份有限公司 | 用于治疗干性老年性黄斑变性(amd)的组合物 |
| WO2024196799A2 (en) * | 2023-03-17 | 2024-09-26 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
| CN117945980A (zh) * | 2024-01-24 | 2024-04-30 | 上海健康医学院 | 一种异吲哚硫亚胺类化合物及其制备和作为sigma-2受体抑制剂的应用 |
| WO2026030341A1 (en) * | 2024-07-29 | 2026-02-05 | Cognition Therapeutics, Inc. | Zervimesine for treating neurodegenerative disease |
| WO2026119142A1 (zh) * | 2024-12-03 | 2026-06-11 | 浙江径科医药有限公司 | 一种氘代异吲哚啉化合物及其应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019089988A1 (en) * | 2017-11-01 | 2019-05-09 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1753662A (zh) * | 2002-12-24 | 2006-03-29 | 神经化学(国际)有限公司 | 用于治疗β-淀粉状蛋白相关疾病的治疗制剂 |
| US20060251714A1 (en) * | 2005-04-12 | 2006-11-09 | Julie Laurin | Pharmaceutical formulations of amyloid inhibiting compounds |
| WO2015116923A1 (en) * | 2014-01-31 | 2015-08-06 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
| US20200000822A1 (en) * | 2017-02-23 | 2020-01-02 | Board Of Regents, The University Of Texas System | Methods of treatment for cancer, sterol homeostasis, and neurological diseases |
| WO2020032027A1 (ja) * | 2018-08-07 | 2020-02-13 | 大日本住友製薬株式会社 | アルツハイマー病の判定薬および判定方法 |
-
2021
- 2021-02-12 KR KR1020227031662A patent/KR20220142477A/ko active Pending
- 2021-02-12 AU AU2021218735A patent/AU2021218735A1/en active Pending
- 2021-02-12 JP JP2022548088A patent/JP2023513220A/ja active Pending
- 2021-02-12 EP EP21754581.3A patent/EP4103604A4/en active Pending
- 2021-02-12 WO PCT/US2021/018023 patent/WO2021163613A1/en not_active Ceased
- 2021-02-12 US US17/798,667 patent/US20230098944A1/en active Pending
- 2021-02-12 CN CN202180027929.1A patent/CN115397849A/zh active Pending
- 2021-02-12 IL IL295427A patent/IL295427A/en unknown
-
2025
- 2025-11-24 JP JP2025202377A patent/JP2026041805A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019089988A1 (en) * | 2017-11-01 | 2019-05-09 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4103604A1 (en) | 2022-12-21 |
| IL295427A (en) | 2022-10-01 |
| WO2021163613A1 (en) | 2021-08-19 |
| EP4103604A4 (en) | 2024-03-27 |
| AU2021218735A1 (en) | 2022-09-01 |
| KR20220142477A (ko) | 2022-10-21 |
| US20230098944A1 (en) | 2023-03-30 |
| JP2026041805A (ja) | 2026-03-10 |
| CN115397849A (zh) | 2022-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2026041805A (ja) | 認知機能低下患者におけるアミロイドβモノマーレベルを減少させる方法 | |
| JP4767982B2 (ja) | 末梢または中枢神経障害およびサイトカイン過剰産生の治療のためのk−252a誘導体の使用 | |
| KR102188487B1 (ko) | 글리타존 및 nrf2 활성화제를 포함하는 약학 조성물 | |
| KR20160067103A (ko) | 신경 장애를 치료하기 위한 토라세미드 및 바클로펜을 포함하는 조성물 | |
| EP3813816B1 (en) | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid in the treatment of fragile x syndrome or fragile x-associated tremor/ataxia syndrome | |
| AU2019443520A1 (en) | A method of treating mental, behavioral, cognitive disorders | |
| AU2016319107A1 (en) | Methods of treating neurodegenerative disorders in a particular patient population | |
| US20160310481A1 (en) | Laquinimod for treatment of cannabinoid receptor type 1(cb1) mediated disorders | |
| JP2024533015A (ja) | 脱髄性の疾患および病状の処置のためのフェンフルラミン | |
| JP2022092013A (ja) | アルツハイマー病を治療するための抗aベータプロトフィブリル抗体及びベータ-セクレターゼbace1阻害剤を含む組成物 | |
| JP7849574B2 (ja) | ゴーシェ病を処置するためのアリモクロモル | |
| JP2007509920A (ja) | 神経変性疾患の治療におけるヒドロキシム酸クロライドの使用 | |
| JP2021523126A (ja) | 蓄積した病理学的Tauタンパク質を低減する方法 | |
| RU2841658C1 (ru) | Способ снижения уровней мономеров бета-амилоида у пациентов со снижением когнитивных способностей | |
| US20240050427A1 (en) | Treatments for obsessive compulsive disorder | |
| HK40083593A (en) | Method of decreasing amyloid beta monomer levels in patients with cognitive decline | |
| US20230301982A1 (en) | N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl)ethynyl]-benzohydrazide for treatment of alzheimer's disease | |
| US11957692B2 (en) | Clomipramine for the treatment of Alzheimer's Disease | |
| WO2025224600A1 (en) | Treatment of alpha-synucleinopathies and neuroprotection | |
| US20180133186A1 (en) | Preventative treatment of alzheimer's disease | |
| WO2025186837A1 (en) | A synergistic bioactive composition for controlling neuromuscular pain and repairing nerve damage | |
| CN118574810A (zh) | 用尼罗加司他治疗卵巢癌 | |
| JP2021532174A (ja) | 慢性外傷性脳症の治療 | |
| HK40050398B (en) | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid in the treatment of fragile x syndrome or fragile x-associated tremor/ataxia syndrome | |
| HK40050398A (en) | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid in the treatment of fragile x syndrome or fragile x-associated tremor/ataxia syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240208 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240208 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241210 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20241211 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250306 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250409 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250515 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20250722 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260103 |